GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (WBO:REGN) » Definitions » Other Net Income (Loss)

Regeneron Pharmaceuticals (WBO:REGN) Other Net Income (Loss) : €0 Mil (TTM As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Regeneron Pharmaceuticals Other Net Income (Loss)?

Regeneron Pharmaceuticals's Other Net Income (Loss) for the three months ended in Jun. 2024 was €-0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Jun. 2024 was €0 Mil.

Regeneron Pharmaceuticals's quarterly Other Net Income (Loss) declined from Dec. 2023 (€0 Mil) to Mar. 2024 (€0 Mil) and declined from Mar. 2024 (€0 Mil) to Jun. 2024 (€-0 Mil).

Regeneron Pharmaceuticals's annual Other Net Income (Loss) stayed the same from Dec. 2021 (€0 Mil) to Dec. 2022 (€0 Mil) but then declined from Dec. 2022 (€0 Mil) to Dec. 2023 (€0 Mil).


Regeneron Pharmaceuticals Other Net Income (Loss) Historical Data

The historical data trend for Regeneron Pharmaceuticals's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Other Net Income (Loss) Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Net Income (Loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regeneron Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Regeneron Pharmaceuticals Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regeneron Pharmaceuticals Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals Business Description

Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

From GuruFocus